• Education
    • Higher Education
    • Scholarships & Grants
    • Online Learning
    • School Reforms
    • Research & Innovation
  • Lifestyle
    • Travel
    • Food & Drink
    • Fashion & Beauty
    • Home & Living
    • Relationships & Family
  • Technology & Startups
    • Software & Apps
    • Startup Success Stories
    • Startups & Innovations
    • Tech Regulations
    • Venture Capital
    • Artificial Intelligence
    • Cybersecurity
    • Emerging Technologies
    • Gadgets & Devices
    • Industry Analysis
  • About us
  • Contact
  • Advertise with Us
  • Privacy & Policy
Today Headline
  • Home
  • World News
    • Us & Canada
    • Europe
    • Asia
    • Africa
    • Middle East
  • Politics
    • Elections
    • Political Parties
    • Government Policies
    • International Relations
    • Legislative News
  • Business & Finance
    • Market Trends
    • Stock Market
    • Entrepreneurship
    • Corporate News
    • Economic Policies
  • Science & Environment
    • Space Exploration
    • Climate Change
    • Wildlife & Conservation
    • Environmental Policies
    • Medical Research
  • Health
    • Public Health
    • Mental Health
    • Medical Breakthroughs
    • Fitness & Nutrition
    • Pandemic Updates
  • Sports
    • Football
    • Basketball
    • Tennis
    • Olympics
    • Motorsport
  • Entertainment
    • Movies
    • Music
    • TV & Streaming
    • Celebrity News
    • Awards & Festivals
  • Crime & Justice
    • Court Cases
    • Cybercrime
    • Policing
    • Criminal Investigations
    • Legal Reforms
No Result
View All Result
  • Home
  • World News
    • Us & Canada
    • Europe
    • Asia
    • Africa
    • Middle East
  • Politics
    • Elections
    • Political Parties
    • Government Policies
    • International Relations
    • Legislative News
  • Business & Finance
    • Market Trends
    • Stock Market
    • Entrepreneurship
    • Corporate News
    • Economic Policies
  • Science & Environment
    • Space Exploration
    • Climate Change
    • Wildlife & Conservation
    • Environmental Policies
    • Medical Research
  • Health
    • Public Health
    • Mental Health
    • Medical Breakthroughs
    • Fitness & Nutrition
    • Pandemic Updates
  • Sports
    • Football
    • Basketball
    • Tennis
    • Olympics
    • Motorsport
  • Entertainment
    • Movies
    • Music
    • TV & Streaming
    • Celebrity News
    • Awards & Festivals
  • Crime & Justice
    • Court Cases
    • Cybercrime
    • Policing
    • Criminal Investigations
    • Legal Reforms
No Result
View All Result
Today Headline
No Result
View All Result
Home Science & Environment Medical Research

New treatment option shows promise for severe hypertrophic cardiomyopathy in children

January 8, 2025
in Medical Research
Reading Time: 3 mins read
A A
0
New treatment option for severe hypertrophic cardiomyopathy in children shows promise
4
SHARES
9
VIEWS
Share on FacebookShare on Twitter


New treatment option for severe hypertrophic cardiomyopathy in children shows promise
Graphical abstract. Credit: JACC: Basic to Translational Science (2024). DOI: 10.1016/j.jacbts.2024.10.002

Trametinib, a mitogen-activated protein kinase (MEK) inhibitor, reduces mortality and morbidity in children with severe hypertrophic cardiomyopathy (HCM) caused by pathogenic variants in the RAS/MAPK pathway, according to a study published in JACC: Basic to Translational Science.

The study provides strong evidence for personalized treatment targeting the underlying genetic causes of RASopathies, a group of rare disorders that often lead to life-threatening cardiac complications.

“Our findings represent a breakthrough in the treatment of HCM in children, particularly those suffering from severe forms of the disease due to genetic variants in the RAS/MAPK pathway,” said Gregor Andelfinger, MD, Ph.D., co-author of the study and a cardiologist at CHU Saint-Justine in Montreal.

“The positive results we observed with trametinib are a promising step forward in addressing an urgent medical need for children whose condition has not responded to standard therapies.”

HCM, a condition where the heart muscle thickens abnormally, is particularly dangerous in children and can lead to heart failure or premature death. About 20% of patients with RASopathies have HCM; RASopathy-associated HCM is often caused by genetic mutations in the RAS/MAPK signaling pathway, which regulates cell growth and development.

It is often a more severe form of HCM and has a higher mortality rate. Until now, treatment options for severe cases of RASopathy-associated HCM (RAS-HCM) in pediatric patients have been limited.

The study, which involved 61 children with severe RAS-HCM, compared 30 children receiving trametinib to 31 children receiving standard care. The results showed a significant reduction in the outcome of death, cardiac transplantation, or the need for cardiac surgery in the trametinib group.

No life-threatening adverse events were observed, although dermatologic and mucous membrane side effects were common but manageable.

“This study provides crucial evidence that targeted therapies like trametinib could dramatically improve the outlook for children suffering from severe HCM,” Andelfinger said. “It underscores the importance of developing genotype-specific therapies for RASopathies and other rare diseases.”

“The paper by Andelfinger and colleagues provides exciting data with respect to treating ‘Rasopathies’ in children with HCM,” said Douglas Mann, MD, FACC, Editor-in-Chief of JACC: Basic to Translational Science. “Rasopathies are a group of rare genetic disorders that are caused by mutations in genes that regulate the Ras/mitogen-activated protein kinase (MAPK) signaling pathway.”

“Given the rarity of this condition and the lack of existing therapies for these children, we felt it was important to publish this paper, with the hope that it will advance the field by providing a foundation for future randomized clinical trials to definitively evaluate the safety and efficacy of Trametinib in children with HCM,” Mann said.

Study limitations include potential biases due to its design and incomplete data collection for the control group. Additionally, the trametinib group included patients with prior heart surgeries, which could affect the results. The shorter follow-up for the trametinib group may also underestimate long-term side effects. Lastly, the study does not determine the optimal dosing of trametinib for RAS-HCM.

More information:
Cordula M. Wolf et al, Impact of MEK Inhibition on Childhood RASopathy-Associated Hypertrophic Cardiomyopathy, JACC: Basic to Translational Science (2024). DOI: 10.1016/j.jacbts.2024.10.002

Provided by
American College of Cardiology


Citation:
New treatment option shows promise for severe hypertrophic cardiomyopathy in children (2025, January 8)
retrieved 8 January 2025
from https://medicalxpress.com/news/2025-01-treatment-option-severe-hypertrophic-cardiomyopathy.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.



New treatment option for severe hypertrophic cardiomyopathy in children shows promise
Graphical abstract. Credit: JACC: Basic to Translational Science (2024). DOI: 10.1016/j.jacbts.2024.10.002

Trametinib, a mitogen-activated protein kinase (MEK) inhibitor, reduces mortality and morbidity in children with severe hypertrophic cardiomyopathy (HCM) caused by pathogenic variants in the RAS/MAPK pathway, according to a study published in JACC: Basic to Translational Science.

The study provides strong evidence for personalized treatment targeting the underlying genetic causes of RASopathies, a group of rare disorders that often lead to life-threatening cardiac complications.

“Our findings represent a breakthrough in the treatment of HCM in children, particularly those suffering from severe forms of the disease due to genetic variants in the RAS/MAPK pathway,” said Gregor Andelfinger, MD, Ph.D., co-author of the study and a cardiologist at CHU Saint-Justine in Montreal.

“The positive results we observed with trametinib are a promising step forward in addressing an urgent medical need for children whose condition has not responded to standard therapies.”

HCM, a condition where the heart muscle thickens abnormally, is particularly dangerous in children and can lead to heart failure or premature death. About 20% of patients with RASopathies have HCM; RASopathy-associated HCM is often caused by genetic mutations in the RAS/MAPK signaling pathway, which regulates cell growth and development.

It is often a more severe form of HCM and has a higher mortality rate. Until now, treatment options for severe cases of RASopathy-associated HCM (RAS-HCM) in pediatric patients have been limited.

The study, which involved 61 children with severe RAS-HCM, compared 30 children receiving trametinib to 31 children receiving standard care. The results showed a significant reduction in the outcome of death, cardiac transplantation, or the need for cardiac surgery in the trametinib group.

No life-threatening adverse events were observed, although dermatologic and mucous membrane side effects were common but manageable.

“This study provides crucial evidence that targeted therapies like trametinib could dramatically improve the outlook for children suffering from severe HCM,” Andelfinger said. “It underscores the importance of developing genotype-specific therapies for RASopathies and other rare diseases.”

“The paper by Andelfinger and colleagues provides exciting data with respect to treating ‘Rasopathies’ in children with HCM,” said Douglas Mann, MD, FACC, Editor-in-Chief of JACC: Basic to Translational Science. “Rasopathies are a group of rare genetic disorders that are caused by mutations in genes that regulate the Ras/mitogen-activated protein kinase (MAPK) signaling pathway.”

“Given the rarity of this condition and the lack of existing therapies for these children, we felt it was important to publish this paper, with the hope that it will advance the field by providing a foundation for future randomized clinical trials to definitively evaluate the safety and efficacy of Trametinib in children with HCM,” Mann said.

Study limitations include potential biases due to its design and incomplete data collection for the control group. Additionally, the trametinib group included patients with prior heart surgeries, which could affect the results. The shorter follow-up for the trametinib group may also underestimate long-term side effects. Lastly, the study does not determine the optimal dosing of trametinib for RAS-HCM.

More information:
Cordula M. Wolf et al, Impact of MEK Inhibition on Childhood RASopathy-Associated Hypertrophic Cardiomyopathy, JACC: Basic to Translational Science (2024). DOI: 10.1016/j.jacbts.2024.10.002

Provided by
American College of Cardiology


Citation:
New treatment option shows promise for severe hypertrophic cardiomyopathy in children (2025, January 8)
retrieved 8 January 2025
from https://medicalxpress.com/news/2025-01-treatment-option-severe-hypertrophic-cardiomyopathy.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.


Tags: Health ResearchHealth Research NewsHealth ScienceMedicine ResearchMedicine Research NewsMedicine Science
Previous Post

Peer support interventions delivered by paid peer and family workers

Next Post

Britain’s Wildlife Baby Boom Continues: There Were No Seals And ‘The next day there were 200’

Related Posts

Autism and ADHD have distinct brain connectivity signatures, study finds

Autism and ADHD have distinct brain connectivity signatures, study finds

May 31, 2025
8

Journalists Draw Link Between Internet Dead Zones, Threatened Medicaid Cuts, and Health

May 31, 2025
8
Next Post

Britain’s Wildlife Baby Boom Continues: There Were No Seals And ‘The next day there were 200’

  • Trending
  • Comments
  • Latest
Family calls for change after B.C. nurse dies by suicide after attacks on the job

Family calls for change after B.C. nurse dies by suicide after attacks on the job

April 2, 2025
Pioneering 3D printing project shares successes

Product reduces TPH levels to non-hazardous status

November 27, 2024

Hospital Mergers Fail to Deliver Better Care or Lower Costs, Study Finds todayheadline

December 31, 2024

Police ID man who died after Corso Italia fight

December 23, 2024
Harris tells supporters 'never give up' and urges peaceful transfer of power

Harris tells supporters ‘never give up’ and urges peaceful transfer of power

0
Des Moines Man Accused Of Shooting Ex-Girlfriend's Mother

Des Moines Man Accused Of Shooting Ex-Girlfriend’s Mother

0

Trump ‘looks forward’ to White House meeting with Biden

0
Catholic voters were critical to Donald Trump’s blowout victory: ‘Harris snubbed us’

Catholic voters were critical to Donald Trump’s blowout victory: ‘Harris snubbed us’

0
China accuses US's Hegseth of 'vilifying' remarks at security forum

China accuses US's Hegseth of 'vilifying' remarks at security forum todayheadline

June 1, 2025

Czech Republic eyes astronaut mission through Axiom Space collaboration

June 1, 2025
A child holds a protest sign with a family member and others opposed to transgender athletes competing.

Transgender track athlete wins gold in California state championships despite Trump threat

June 1, 2025
South Korea Presidential candidates rally ahead of June 3 vote

South Korea Presidential candidates rally ahead of June 3 vote

June 1, 2025

Recent News

China accuses US's Hegseth of 'vilifying' remarks at security forum

China accuses US's Hegseth of 'vilifying' remarks at security forum todayheadline

June 1, 2025
3

Czech Republic eyes astronaut mission through Axiom Space collaboration

June 1, 2025
4
A child holds a protest sign with a family member and others opposed to transgender athletes competing.

Transgender track athlete wins gold in California state championships despite Trump threat

June 1, 2025
3
South Korea Presidential candidates rally ahead of June 3 vote

South Korea Presidential candidates rally ahead of June 3 vote

June 1, 2025
3

TodayHeadline is a dynamic news website dedicated to delivering up-to-date and comprehensive news coverage from around the globe.

Follow Us

Browse by Category

  • Africa
  • Asia
  • Basketball
  • Business & Finance
  • Climate Change
  • Crime & Justice
  • Cybersecurity
  • Economic Policies
  • Elections
  • Entertainment
  • Entrepreneurship
  • Environmental Policies
  • Europe
  • Football
  • Gadgets & Devices
  • Health
  • Medical Research
  • Mental Health
  • Middle East
  • Motorsport
  • Olympics
  • Politics
  • Public Health
  • Relationships & Family
  • Science & Environment
  • Software & Apps
  • Space Exploration
  • Sports
  • Stock Market
  • Technology & Startups
  • Tennis
  • Travel
  • Uncategorized
  • Us & Canada
  • Wildlife & Conservation
  • World News

Recent News

China accuses US's Hegseth of 'vilifying' remarks at security forum

China accuses US's Hegseth of 'vilifying' remarks at security forum todayheadline

June 1, 2025

Czech Republic eyes astronaut mission through Axiom Space collaboration

June 1, 2025
  • Education
  • Lifestyle
  • Technology & Startups
  • About us
  • Contact
  • Advertise with Us
  • Privacy & Policy

© 2024 Todayheadline.co

Welcome Back!

OR

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Business & Finance
  • Corporate News
  • Economic Policies
  • Entrepreneurship
  • Market Trends
  • Crime & Justice
  • Court Cases
  • Criminal Investigations
  • Cybercrime
  • Legal Reforms
  • Policing
  • Education
  • Higher Education
  • Online Learning
  • Entertainment
  • Awards & Festivals
  • Celebrity News
  • Movies
  • Music
  • Health
  • Fitness & Nutrition
  • Medical Breakthroughs
  • Mental Health
  • Pandemic Updates
  • Lifestyle
  • Fashion & Beauty
  • Food & Drink
  • Home & Living
  • Politics
  • Elections
  • Government Policies
  • International Relations
  • Legislative News
  • Political Parties
  • Africa
  • Asia
  • Europe
  • Middle East
  • Artificial Intelligence
  • Cybersecurity
  • Emerging Technologies
  • Gadgets & Devices
  • Industry Analysis
  • Basketball
  • Football
  • Motorsport
  • Olympics
  • Climate Change
  • Environmental Policies
  • Medical Research
  • Science & Environment
  • Space Exploration
  • Wildlife & Conservation
  • Sports
  • Tennis
  • Technology & Startups
  • Software & Apps
  • Startup Success Stories
  • Startups & Innovations
  • Tech Regulations
  • Venture Capital
  • Uncategorized
  • World News
  • Us & Canada
  • Public Health
  • Relationships & Family
  • Travel
  • Research & Innovation
  • Scholarships & Grants
  • School Reforms
  • Stock Market
  • TV & Streaming
  • Advertise with Us
  • Privacy & Policy
  • About us
  • Contact

© 2024 Todayheadline.co